"As the field of breast MRI advances, we are entering an exciting time where the power of the contrast mechanisms of MRI can be used to classify lesions. Morphological analysis, lesion kenetics, diffusion contrast coupled with high quality breast MRI images produced by Sentinelle's line of MRI coils is leading to advancements in lesion detection and differentiation," says Cameron Piron, CEO of Sentinelle Medical. "Partnering with Medipattern allows us to launch a next-generation platform that will utilize these developments in an efficient, effective and adaptive manner. Streamlining morphology analysis is a challenging problem that requires a combination of Medipattern technology with Sentinelle MRI know-how. We are very excited about the potential impact this will have in the fight against breast cancer".
"Sentinelle is well positioned to make major advancements in Breast MRI technology. Medipattern is well served to partner with Sentinelle to deliver its Breast MRI CAD to the market," states Jeff Collins, Medipattern's President and CEO. "Medipattern was founded to help physicians in their pursuit of finding and identifying breast cancer earlier when it is more treatable. Sentinelle and Medipattern are perfectly aligned toward this great goal. We are pleased to work with Sentinelle."
Sentinelle products are used in leading breast cancer and imaging centers throughout North America including Dartmouth-Hitchcock Medical Centre, H. Lee Moffitt Cancer Center and Research Institute, Mountain Medical Physician Specialists, Radiology Ltd., Scripps Memorial Hospital, Sunnybrook Health Sciences Centre, University Health Network and Windsong Radiology Group.
2009 Upcoming Events:
RSNA (Radiological Society of North America), November 29 to December 3, 2009, Chicago, IL In the Medipattern booth 1009, PenRad Booth 4600, and the GE Healthcare Booth 4029Source: Medipattern Corporation